A Phase III Randomized, Open-Label, Multi-Center Study of MEDI4736 in Combination with Tremelimumab Therapy or MEDI4736 Monotherapy Versus Standard of Care Platinum-Based Chemotherapy in First Line Treatment of Patients in Asia Pacific with Advanced Non Small-Cell Lung Cancer (NSCLC)
Phase 3
- Conditions
- ung cancer
- Registration Number
- TCTR20161027002
- Lead Sponsor
- Astrazeneca (Thailand) Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending (Not yet recruiting)
- Sex
- All
- Target Recruitment
- 86
Inclusion Criteria
-Stage IV NSCLC
-Age > 18 years
-No prior systemic treatment for stage IV NSCLC
Exclusion Criteria
- Other primary malignancy
- Active infection
- Any concurrent diseases not suitable for the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method PFS every 6 weeks Imaging,OS every 12 weeks vital status
- Secondary Outcome Measures
Name Time Method safety every 4 weeks adverse event report